No phaseCompleted
Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes (PREDICT)
Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk
- Sponsor
- Garvan Institute of Medical Research (Academic or other)
- Enrolment
- 138 enrolled
- Conditions
- Pre Diabetes; Type 2 Diabetes Mellitus
- Interventions
- Metformin + Healthy diet; Metformin + Personalized diet
- Ages
- adults, older adults
- Registry
- NCT03558867
Full record on ClinicalTrials.gov
From the registry
Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer. Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently. The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.
Primary outcomes
- Mean change in glycated haemoglobin (HbA1C, %) from baseline
History
Last registry update
Study completion
Primary completion
Registered
Started